share_log
Reuters ·  Mar 11 12:30
Actinium Pharmaceuticals Announces Initiation of Actimab-a Triplet Combination Frontline Trial Under Nci Crada With Venetoclax and Taiho Oncology's Hypomethylating Agent Astx-727 in Patients With Newly Diagnosed Aml
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Write a comment